Clinical Research Directory
Browse clinical research sites, groups, and studies.
Second Window Indocyanine Green for All Nervous System Tumors
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
The study is being conducted to determine if a same-day, low-dose intravenous (into a vein) injection of indocyanine green (ICG) (FDA-approved dye) being detected by using an imaging system can be a useful tool in identifying and differentiating tumor tissue from normal tissues.
Official title: Intraoperative Molecular Imaging of Central Nervous System Tumors Using Same Day Second Window Imaging With Indocyanine Green (TumorGlow™ - CNS)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
105
Start Date
2023-03-31
Completion Date
2027-02-15
Last Updated
2026-01-22
Healthy Volunteers
No
Conditions
Interventions
Administration of Indocyanine Green (ICG) and Visualization of Tumor
A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
Locations (1)
Pennsylvania Hospital
Philadelphia, Pennsylvania, United States